BioSpace News Archive

Medical devices reimbursement refers to a payment made for the purpose of covering the cost of medical devices. A public or a private insurer makes the payment to a healthcare provider.

Premier is one of the leading healthcare improvement companies in the United States, uniting an alliance of approximately 4,100 US hospitals and 200,000 providers.

Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry Co., Ltd.

American Lung Association’s new report examines toll of lung cancer state-by-state, identifies opportunities to save lives with screening

Boston Scientific Corporation has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system.

The Bristol Myers Squibb Foundation and National Medical Fellowships today announced that they have entered into a partnership aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment from Bristol Myers Squibb and

Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (“Common Shares”) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (“Consolidation”). Complet

With recent announcements that pharmaceutical companies are close to supplying an initial vaccine to combat the COVID-19 virus around the world, global logistics experts are stepping up to support what will be an epic supply chain challenge.

RATIONALE 303 is a global Phase 3 trial of BeiGene’s anti-PD-1 antibody tislelizumab compared to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who progressed on prior platinum-based chemotherapy

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020. The data presented will be a part of the event’s Spotlight Session Poster Presenters. Details of the presentation are as follows: Title - Describing the cancer spectru